|Mr. Kenneth L. Waggoner Esq.||Chairman, CEO, Pres, Gen. Counsel & Sec.||433.33k||N/A||1948|
|Mr. Carlos A. Trujillo CPA, CPA||CFO & Director||300k||N/A||1958|
|Dr. Gerald W. Crabtree Ph.D.||Chief Scientific Officer & Director||94.33k||N/A||1941|
|Dr. Jose L. Iglesias M.D.||Consulting Chief Medical Officer||N/A||N/A||1957|
|Dr. Hans-Peter Hammes||Member of Medical & Scientific Advisory Board and Consultant||N/A||N/A||N/A|
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other tumors, including encapsulated genetically modified living cells. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. The company has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is based in Laguna Hills, California.
PharmaCyte Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.